RT @AurelieRheumo: 18mo data of ARIAA study (6mo ABA in pre-RA): 12mo after discontinuation Progression to RA ABA 35% vs
Tweet Content
18mo data of ARIAA study (6mo ABA in pre-RA):
12mo after discontinuation
Progression to RA ABA 35% vs PBO 57% p=0.008
Improvement in synovitis, osteitis & tenosynovitis ABA 57% vs. 29% PBO
Enough to move into clinical application?
https://t.co/2CDN9M31mB
Abs#0530 #ACR22 @Rheumnow https://t.co/R54AokGSiK
Links
Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Mo…
http://bit.ly/3hBUxB7
Show on Archive Page
On
Display in Search Results
On
PDQ
Off